11 unchanged sentences
Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
−Removed: Under the supervision and with the participation of our management , including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the 2013 framework in Internal Control–Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.
+Added: Under the supervision and with the participation of our management , including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial
+Added: reporting based on the 2013 framework in Internal Control–Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on our evaluation under that framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2020.
3 unchanged sentences
Report of Independent Registered Public Accounting Firm
−Removed: To the Shareholders and the Board of Directors of Editas Medicine, Inc.
+Added: To the Stockholders and the Board of Directors of Editas Medicine, Inc.
Opinion on Internal Control over Financial Reporting
3 unchanged sentences
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Editas Medicine Inc.
−Removed: as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders’ (deficit) equity, and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and our report dated February 26, 2020 expressed an unqualified opinion thereon.
+Added: as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes and our report dated February 26, 2021 expressed an unqualified opinion thereon.
Basis for Opinion
49 unchanged sentences
Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan, as amended
+Added: Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan, as amended
Incorporated by Reference
Description of Exhibit
−Removed: Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan, as amended
Form of Early Exercise Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan, as amended
7 unchanged sentences
Employment Offer Letter, dated August 6, 2019, between the Registrant and Cynthia Collins
−Removed: Employment Offer Letter, dated October 11, 2019, between the Registrant and Judith R.
+Added: Letter Agreement, dated February 15, 2021, by and between the Registrant and Cynthia Collins
+Added: Employment Offer Letter, dated February 14, 2021, between the Registrant and James C.
Employment Offer Letter, dated December 27, 2019, between the Registrant and Michelle Robertson
1 unchanged sentence
Form of Inducement Restricted Stock Unit Award Agreement for the Registrant’s executive officers
−Removed: Letter Agreement, dated September 26, 2019, by and between the Registrant and Vic Myer, Ph.D.
+Added: Employment Offer Letter, dated September 25, 2020, between the Registrant and Lisa A.
+Added: Michaels, M.D.
Amended and Restated Cas9-I License Agreement, dated December 16, 2016, among the Registrant, the President and Fellows of Harvard College (“Harvard”), and the Broad Institute, Inc.
1 unchanged sentence
Amendment No.1 to Amended and Restated Cas9-I License Agreement, by and among Editas Medicine, Inc., Harvard, and Broad, dated March 3, 2017
−Removed: Incorporated by Reference
−Removed: Description of Exhibit
Second Amended and Restated License and Collaboration Agreement, dated November 11, 2019, between the Registrant and Juno Therapeutics, Inc.
1 unchanged sentence
Sponsored Research Agreement, dated June 7, 2018, between the Registrant and Broad
+Added: Incorporated by Reference
+Added: Description of Exhibit
+Added: First Amendment to Sponsored Research Agreement, dated January 11, 2021, between the Registrant and Broad
Summary of Director Compensation Program
6 unchanged sentences
Cas9-II License Agreement, dated as of December 16, 2016, by and between the Registrant and Broad
+Added: Omnibus Amendment, dated as of January 11, 2021, by and between the Registrant and Broad
Letter Agreement, dated as of November 18, 2019, by and among, the Registrant, Broad and Harvard
Letter Agreement, dated as of December 16, 2019, by and among, the Registrant, Broad and Harvard
−Removed: Strategic Alliance and Option Agreement, dated March 14, 2017, by and between the Registrant and Allergan Pharmaceuticals International Limited
−Removed: Co-Development and Commercialization Agreement, dated February 22, 2019, by and between the Registrant and Allergan Sales, LLC
+Added: Common Stock Sales Agreement, dated as of May 15, 2020, by and between the Company and Cowen and Company, LLC
+Added: Termination Agreement, dated August 5, 2020, by and between the Registrant and Allergan Sales, LLC
Subsidiaries of the Registrant
3 unchanged sentences
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.
−Removed: Incorporated by Reference
−Removed: Description of Exhibit
The following financial statements from the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, formatted in Inline XBRL (eXtensible Business Reporting Language):
9 unchanged sentences
February 26, 2021
−Removed: /s/ Cynthia Collins
−Removed: Cynthia Collins
Principal Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
−Removed: /s/ Cynthia Collins
−Removed: President and Chief Executive Officer, Director (principal executive officer)
+Added: President and Chief Executive Officer, Chairman of the Board (principal executive officer)
February 26, 2021
−Removed: Cynthia Collins
/s/ Michelle Robertson
2 unchanged sentences
Michelle Robertson
−Removed: /s/ James Mullen
−Removed: Chairman of the Board
+Added: /s/ Meeta Chatterjee
February 26, 2021
+Added: Meeta Chatterjee, Ph.D.
/s/ Andrew Hirsch
11 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.